Amylyx Pharmaceuticals (AMLX) Total Non-Current Liabilities (2022)
Amylyx Pharmaceuticals' (AMLX) quarterly Total Non-Current Liabilities came in at $49.5 million in Q4 2022.
Amylyx Pharmaceuticals (AMLX) Total Non-Current Liabilities (2022) Analysis & Trends
Amylyx Pharmaceuticals' Total Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $49.5 million for Q4 2022.
- On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $49.5 million in Q4 2022; TTM through Dec 2022 was $49.5 million, a N/A change from a year earlier, with the FY2022 full-year figure at $49.5 million, changed N/A from the prior year.
- Total Non-Current Liabilities was little changed at $49.5 million in Q4 2022 per AMLX's latest filing.
- Across five years, Total Non-Current Liabilities topped out at $49.5 million in Q4 2022 and bottomed at $49.5 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Amylyx Pharmaceuticals | 1.94 Bn | 1.94 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 49.49 Mn |